Global Scleroderma Treatment Market 2017-2021

  • ID: 4319169
  • Report
  • Region: Global
  • 83 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Amgen
  • Bayer AG
  • Boehringer Ingelheim
  • Corbus Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Scleroderma Treatment

Scleroderma is an autoimmune disorder, which is a condition when body’s tissues get attacked by the immune system. The term scleroderma is defined as the hardening of the skin; however, it is much more than the skin disorder. The disease is characterized by microvascular injury and fibrosis in the affected organs.

The analysts forecast the global scleroderma treatment market to grow at a CAGR of 7.02% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global scleroderma treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Scleroderma Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Pfizer

Other prominent vendors

  • Amgen
  • Bayer AG
  • Boehringer Ingelheim
  • Biogen
  • CELGENE
  • Corbus Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Novartis
  • Sanofi

Market drivers

  • High unmet medical needs
  • For a full, detailed list, view the full report

Market challenges

  • Unknown pathogenesis of the disorder
  • For a full, detailed list, view the full report

Market trends

  • Partnerships and strategic alliances
  • For a full, detailed list, view the full report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • Bayer AG
  • Boehringer Ingelheim
  • Corbus Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
  • Scleroderma disease overview
  • Market landscape
  • Market overview
  • Five forces analysis
PART 05: Pipeline landscape

PART 06: Market segmentation by drug class
  • Anti-inflammatory drugs
  • Immunosuppressants
  • Others
  • PDE5 inhibitors
  • Calcium channel blockers
PART 07: Geographical segmentation
  • Scleroderma treatment market in Americas
  • Scleroderma treatment market in EMEA
  • Scleroderma treatment market in APAC
PART 08: Decision framework

PART 09: Drivers and challenges
  • Market drivers
  • Market challenges
PART 10: Market trends
    PARTnerships and strategic alliances
    • Introduction of stem cells in scleroderma treatment
    • Advent of novel therapies
    PART 11: Vendor landscape
    • Competitive scenario
    PART 12: Key vendor analysis
    • AstraZeneca
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Pfizer
    • Other prominent vendors
    PART 13: Appendix
    • List of abbreviations
    List of Exhibits
    Exhibit 01: Types of scleroderma
    Exhibit 02: Global scleroderma treatment market snapshot
    Exhibit 03: Global scleroderma treatment market 2016-2021 ($ millions)
    Exhibit 04: Opportunity analysis in global scleroderma treatment market
    Exhibit 05: Five forces analysis
    Exhibit 06: Number of pipeline molecules by vendors at various phases
    Exhibit 07: Key clinical trials
    Exhibit 08: Global scleroderma treatment market by drug class
    Exhibit 09: Side effects associated with anti-inflammatory drug class
    Exhibit 10: Global scleroderma anti-inflammatory drugs market 2016-2021 ($ millions)
    Exhibit 11: Drivers and challenges of anti-inflammatory drugs
    Exhibit 12: Side effects associated with immunosuppressants
    Exhibit 13: Global scleroderma immunosuppressants market 2016-2021 ($ millions)
    Exhibit 14: Drivers and challenges of immunosuppressants
    Exhibit 15: Global scleroderma treatment market by others drug class 2016-2021 ($ millions)
    Exhibit 16: Major drug classes included in the others segment
    Exhibit 17: Side effects associated with PDE5 inhibitors
    Exhibit 18: Global scleroderma PDE5 inhibitors market 2016-2021 ($ millions)
    Exhibit 19: Drivers and challenges of PDE5 inhibitors
    Exhibit 20: Side effects associated with calcium channel blockers
    Exhibit 21: Global scleroderma calcium channel blockers market 2016-2021 ($ millions)
    Exhibit 22: Drivers and challenges of calcium channel blockers
    Exhibit 23: Global scleroderma treatment market segmentation based on geography 2016 and 2021 (%)
    Exhibit 24: Global scleroderma treatment market revenue by geography 2016-2021 ($ millions)
    Exhibit 25: Market scenario in Americas
    Exhibit 26: Scleroderma treatment market in Americas 2016-2021 ($ millions)
    Exhibit 27: Market scenario in EMEA
    Exhibit 28: Scleroderma treatment market in EMEA 2016-2021 ($ millions)
    Exhibit 29: Market scenario in APAC
    Exhibit 30: Scleroderma treatment market in APAC 2016-2021 ($ millions)
    Exhibit 31: Promising new projects in scleroderma studies
    Exhibit 32: Potential therapeutic targets involved in numerous studies for scleroderma
    Exhibit 33: Strategic success factors of companies in global scleroderma treatment market
    Exhibit 34: AstraZeneca: Key highlights
    Exhibit 35: AstraZeneca: Strength assessment
    Exhibit 36: AstraZeneca: Strategy assessment
    Exhibit 37: AstraZeneca: Opportunity assessment
    Exhibit 38: F. Hoffmann-La Roche: Key highlights
    Exhibit 39: F. Hoffmann-La Roche: Strength assessment
    Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
    Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
    Exhibit 42: GlaxoSmithKline: Key highlights
    Exhibit 43: GlaxoSmithKline: Strength assessment
    Exhibit 44: GlaxoSmithKline: Strategy assessment
    Exhibit 45: GlaxoSmithKline: Opportunity assessment
    Exhibit 46: Pfizer: Key highlights
    Exhibit 47: Pfizer: Strength assessment
    Exhibit 48: Pfizer: Strategy assessment
    Exhibit 49: Pfizer: Opportunity assessment
    Note: Product cover images may vary from those shown
    3 of 5

    Loading
    LOADING...

    4 of 5

    FEATURED COMPANIES

    • Amgen
    • Bayer AG
    • Boehringer Ingelheim
    • Corbus Pharmaceuticals
    • GlaxoSmithKline
    • Merck
    • MORE
    1h Free Analyst Time

    Speak directly to the analyst to clarify any post sales queries you may have.

    New Report Released: – Global Scleroderma Treatment Market 2017-2021

    The author of the report recognizes the following companies as the key players in the global scleroderma treatment market: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Pfizer.

    Other Prominent Vendors in the market are: Amgen, Bayer AG, Boehringer Ingelheim, Biogen, CELGENE, Corbus Pharmaceuticals, Johnson & Johnson, Merck, Novartis, and Sanofi.

    Commenting on the report, an analyst from the research team said: “One trend in the market is partnerships and strategic alliances. Partnerships among research foundations and pharmaceutical companies are expected to bring new therapeutics for the treatment of scleroderma. Strategic alliances formed, in terms of licensing and collaboration, help in the co-development and commercialization of drugs in different regions.”

    According to the report, one driver in the market is high unmet medical needs. The unknown etiology of autoimmune diseases such as scleroderma prevents the introduction of innovative drugs that can treat their exact cause. Some of the most common drugs classes used for the treatment of scleroderma are corticosteroids, immunosuppressive agents, and NSAIDs. Most of these drugs are used off-label for these indications. Any drug that can provide a complete cure with minimal side effects will experience widespread adoption in the market.

    Further, the report states that one challenge in the market is unknown pathogenesis of the disorder. The pathogenesis and etiology of scleroderma are still unknown. This makes the treatment and management of the disease even more difficult. Autoimmune diseases such as scleroderma are chronic, and they affect multiple organs. Sometimes, the patient weakens even during treatment. The cause of scleroderma is debatable.

    The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
    Note: Product cover images may vary from those shown
    5 of 5
    1h Free Analyst Time

    Speak directly to the analyst to clarify any post sales queries you may have.

    • Amgen
    • AstraZeneca
    • Bayer AG
    • Biogen
    • Boehringer Ingelheim
    • CELGENE
    • Corbus Pharmaceuticals
    • F Hoffmann-La Roche
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
    • Novartis
    • Pfizer
    • Sanofi
    Note: Product cover images may vary from those shown
    6 of 5
    Note: Product cover images may vary from those shown
    Adroll
    adroll